Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Ihnen/SKU | Verfügbarkeit | Preis |
|---|---|---|
10 mg | Warenkorb auf Verfügbarkeit prüfen | € 117,00 |
50 mg | Warenkorb auf Verfügbarkeit prüfen | € 388,00 |
Über diesen Artikel
Empirische Formel (Hill-System):
C9H22NNaO7P2
CAS-Nummer:
Molekulargewicht:
341.21
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41106300
MDL number:
Assay:
≥97% (NMR)
Form:
solid
Storage condition:
protect from light
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Segment
assay
≥97% (NMR)
form
solid
storage condition
protect from light
color
white
solubility
H2O: >10 mg/mL
originator
Roche
storage temp.
2-8°C
SMILES string
[Na+].CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O
InChI
1S/C9H23NO7P2.Na/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);/q;+1/p-1
InChI key
LXLBEOAZMZAZND-UHFFFAOYSA-M
Gene Information
human ... FDPS(2224)
Application
Ibandronate sodium salt has been used to study its effect on the proliferation and ultrastructure of Leishmania and Giardia by the generation of concentration curves. It has also been used to elucidate the route by which nitrogen-containing bisphosphonates (N-BPs) enter the cytosol and inhibit their molecular target.
Biochem/physiol Actions
Ibandronate sodium inhibits farnesyl diphosphate synthase (IC50 = 20 nM). Ibandronate sodium is also a bone resorption inhibitor. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.
Ibandronate sodium is a farnesyl diphosphate synthase inhibitor (IC50 = 20 nM); also a bone resorption inhibitor.
Ibandronate is a nitrogen-containing bisphosphonate (N-BP). It potentially inhibits mevalonate pathway in osteoclasts. Thus, ibandronate is effectively used to treat osteoporosis and other bone-related diseases.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description ≥97% (NMR), solid | description ≥97% (NMR), powder | description ≥95% (NMR), solid | description ≥97% (NMR), solid |
| form solid | form powder | form solid | form solid |
| assay ≥97% (NMR) | assay ≥97% (NMR) | assay ≥95% (NMR) | assay ≥97% (NMR) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. 2-8°C | storage temp. −20°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility H2O: >10 mg/mL | solubility water, double-distilled: 10 mg/mL | solubility H2O: 28 mg/mL | solubility H2O: >5 mg/mL |
| storage condition protect from light | storage condition - | storage condition - | storage condition - |
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.



